Dtsch Med Wochenschr 2013; 138(49): 2515-2518
DOI: 10.1055/s-0033-1359870
Hämatologie & Onkologie | Commentary
Onkologie, Neurologie
© Georg Thieme Verlag KG Stuttgart · New York

Therapie primär zerebraler Lymphome

Primary CNS lymphoma
G. Illerhaus
1   Stuttgart Cancer Center (SCC) – Tumorzentrum Eva Mayr-Stihl, Klinikum Stuttgart
› Author Affiliations
Further Information

Publication History

Publication Date:
26 November 2013 (online)

    Permissions and Reprints

Schlüsselwörter

zerebrale Lymphome - ZNS-Lymphome - Non-Hodgkin-Lymphome - Hirntumoren

Keywords

primary CNS lymphoma - PCNSL - non-Hodgkin lymphoma - brain tumors
 

  • Literatur

  • 1 Abrey LE, Moskowitz CH, Mason WP et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma. J Clin Oncol 2003; 21: 151-156
    Google Scholar
  • 2 Bataille B, Delwail V, Menet E et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 2000; 92: 261-266
    CrossrefGoogle Scholar
  • 3 Batchelor T, Carson K, O'Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy. J Clin Oncol 2003; 21: 1044-1049
    CrossrefGoogle Scholar
  • 4 Ferreri AJ, Reni M, Foppoli M et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374: 1512-1520
    CrossrefGoogle Scholar
  • 5 Fritsch K, Kasenda B, Hader C et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol 2011; 22: 2080-2085
    CrossrefGoogle Scholar
  • 6 Herrlinger U, Kuker W, Uhl M et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005; 57: 843-847
    CrossrefGoogle Scholar
  • 7 Illerhaus G, Fritsch K, Egerer G et al. Sequential high dose immuno-chemotherapy followed by autologous peripheral blood stem cell transplantation for patients with untreated primary central nervous system lymphoma – a multicentre study by the Collaborative PCNSL Study Group Freiburg. Blood 2012; 120 Abstr. 302
    Google Scholar
  • 8 Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24: 3865-3870
    CrossrefGoogle Scholar
  • 9 Illerhaus G, Marks R, Muller F et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009; 20: 319-325
    Google Scholar
  • 10 Juergens A, Pels H, Rogowski S et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010; 67: 182-189
    CrossrefGoogle Scholar
  • 11 Kasenda B, Schorb E, Fritsch K et al. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma – a long-term follow-up study. Ann Oncol 2012; 23: 2670-2675
    CrossrefGoogle Scholar
  • 12 Pels H, Schmidt-Wolf IG, Glasmacher A et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21: 4489-4495
    CrossrefGoogle Scholar
  • 13 Plotkin SR, Betensky RA, Hochberg FH et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10: 5643-5646
    CrossrefGoogle Scholar
  • 14 Soussain C, Hoang-Xuan K, Taillandier L et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008; 26: 2512-2518
    CrossrefGoogle Scholar
  • 15 Thiel E, Korfel A, Martus P et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11: 1036-1047
    CrossrefGoogle Scholar